Praxis Precision Medicines, Inc.

Approval AI-extracted

ulixacaltamide

essential tremor

Date

TBD

Approval decision · Date TBD estimated

What's at stake A final FDA approval decision on ulixacaltamide for essential tremor is expected Date TBD.

Primary source · SEC 8-K verified 14h ago

“Following a positive pre-NDA meeting with the FDA in December 2025, Praxis has submitted an NDA for the treatment of ET.”